BIOSPECIMEN, PATHOLOGY, AND PHARMACOLOGY

生物标本、病理学和药理学

• 批准号: 6990047
• 负责人: ROBERT A. NEWMAN
• 金额: $ 28.25万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-08-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6990047
• 关键词: biomedical facility; drug screening /evaluation; human tissue; mass spectrometry; mouth neoplasms; pathology; pharmacogenetics; proteomics; sample collection; tissue /cell preparation; tissue resource /registry

DESCRIPTION (provided by applicant): Core C will play a central and critical role in this P01. Three types of services will be provided. These are: A. Biospecimen Procurement, Handling and Distribution: A major function of the CORE will be to serve as a central site for receiving, cataloging, storing and redistributing samples from Nordic countries to the NRH. In addition, samples will then be sent to MDACC for redistribution and analyses there. B. Pathology Services: The second main objective will involve a coordinated effort by the Nordic pathology team headed by Dr. Reith and Dr. Adel EI-Naggar at MDACC who will implement standardized criteria for biomarker scoring and evaluation. They will coordinate and provide professional services for proper handling and processing of histopathologic materials. C. Pharmacology Services: This part of Core C will provide a number of pharmacology services that include analyses of plasma drug levels of Celecoxib and EKB-569 as well as eicosanoid metabolism within clinical biopsy specimens and animal tissues. Eicosanoids will be determined using a highly specialized tandem mass spectrometry procedure developed by the Director of this Core, Dr. Newman. In addition, mass spectrometry analyses of peptides will provide support to Dr. Mao's proteomics research in Project 3. As the clinical trial progresses to attain the targeted sample size, more Core effort will be required in the preparation and distribution of tissue sections for the translational research projects. The role of this Core will become increasingly important because proposed studies and further progress in the field of carcinogenesis research may identify new cellular, biochemical, or molecular genetic markers of interest. These will need to be tested and expanded using the tissue samples obtained through this project.

描述（由申请人提供）：核心 C 将在此 P01 中发挥核心和关键作用。将提供三种类型的服务。这些都是： A. 生物样本采购、处理和分发：CORE 的主要功能是作为从北欧国家接收、编目、存储和重新分发来自北欧国家的样本到 NRH 的中心站点。此外，样本随后将被发送至 MDACC 进行重新分发和分析。 B. 病理学服务：第二个主要目标将涉及北欧国家的协调努力 MDACC 的 Reith 博士和 Adel EI-Naggar 博士领导的病理学团队将实施 生物标志物评分和评估的标准化标准。他们将协调并提供 正确处理和加工组织病理学材料的专业服务。 C. 药理学服务：核心 C 的这一部分将提供多种药理学服务，包括分析塞来昔布和 EKB-569 的血浆药物水平以及临床活检标本和动物组织中的类二十烷酸代谢。将使用由该核心主任 Newman 博士开发的高度专业化的串联质谱程序来测定类二十烷酸。此外，多肽的质谱分析将为毛博士在项目3中的蛋白质组学研究提供支持。随着临床试验的进展达到目标样本量，在转化实验的组织切片的制备和分配方面将需要更多的核心努力。研究项目。该核心的作用将变得越来越重要，因为致癌研究领域的拟议研究和进一步进展可能会识别出新的感兴趣的细胞、生化或分子遗传标记。这些需要使用通过该项目获得的组织样本进行测试和扩展。